These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 31551292)

  • 61. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients.
    Xiang B; Zhao X; Zhou X
    Cardiovasc Diabetol; 2021 Apr; 20(1):78. PubMed ID: 33827579
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2019 Feb; 18(1):19. PubMed ID: 30819188
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Risk stratification tools for heart failure in the diabetes clinic.
    Cannistraci R; Mazzetti S; Mortara A; Perseghin G; Ciardullo S
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1070-1079. PubMed ID: 32475628
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i.
    Lamacchia O; Sorrentino MR
    Curr Vasc Pharmacol; 2021; 19(2):233-240. PubMed ID: 32183678
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes.
    Cattadori G; Pantanetti P; Ambrosio G
    Diabetes Res Clin Pract; 2019 Nov; 157():107835. PubMed ID: 31479706
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
    Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New Antidiabetes Medications and Their Cardiovascular and Renal Benefits.
    Ferro EG; Elshazly MB; Bhatt DL
    Cardiol Clin; 2021 Aug; 39(3):335-351. PubMed ID: 34247748
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 70. How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?
    Tanaka A; Node K
    Cardiovasc Diabetol; 2020 Dec; 19(1):206. PubMed ID: 33287812
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature Review.
    Okere AN; Montesdeoca J; Glasper A; Diaby V
    Curr Diabetes Rev; 2018; 14(4):363-375. PubMed ID: 28738763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes.
    Berg DD; Kolkailah AA; Sarraju A; Kerchberger AM; Eljalby M; McGuire DK
    Curr Diab Rep; 2021 Nov; 21(11):45. PubMed ID: 34741199
    [TBL] [Abstract][Full Text] [Related]  

  • 75. How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?
    Sukkar L; Young T; Jardine MJ
    Kidney Blood Press Res; 2020; 45(6):823-836. PubMed ID: 33271545
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
    Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus].
    Gorgojo-Martínez JJ
    Hipertens Riesgo Vasc; 2019; 36(3):145-161. PubMed ID: 31079957
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
    Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
    Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.
    Kim GS; Park JH; Won JC
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):106-116. PubMed ID: 31099200
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.
    Wu L; Gunton JE
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.